These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 28375027)

  • 1. Characterisation of data resources for in silico modelling: benchmark datasets for ADME properties.
    Przybylak KR; Madden JC; Covey-Crump E; Gibson L; Barber C; Patel M; Cronin MTD
    Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):169-181. PubMed ID: 28375027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico ADME-Tox modeling: progress and prospects.
    Alqahtani S
    Expert Opin Drug Metab Toxicol; 2017 Nov; 13(11):1147-1158. PubMed ID: 28988506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In silico prediction of ADME properties: are we making progress?
    Beresford AP; Segall M; Tarbit MH
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):36-42. PubMed ID: 14982146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In silico approaches for predicting ADME properties of drugs.
    Yamashita F; Hashida M
    Drug Metab Pharmacokinet; 2004 Oct; 19(5):327-38. PubMed ID: 15548844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent progresses in the exploration of machine learning methods as in-silico ADME prediction tools.
    Tao L; Zhang P; Qin C; Chen SY; Zhang C; Chen Z; Zhu F; Yang SY; Wei YQ; Chen YZ
    Adv Drug Deliv Rev; 2015 Jun; 86():83-100. PubMed ID: 26037068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-silico ADME models: a general assessment of their utility in drug discovery applications.
    Gleeson MP; Hersey A; Hannongbua S
    Curr Top Med Chem; 2011; 11(4):358-81. PubMed ID: 21320065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting ADME properties and side effects: the BioPrint approach.
    Krejsa CM; Horvath D; Rogalski SL; Penzotti JE; Mao B; Barbosa F; Migeon JC
    Curr Opin Drug Discov Devel; 2003 Jul; 6(4):470-80. PubMed ID: 12951810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 1: goals, properties of the PhRMA dataset, and comparison with literature datasets.
    Poulin P; Jones HM; Jones RD; Yates JW; Gibson CR; Chien JY; Ring BJ; Adkison KK; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Ku MS
    J Pharm Sci; 2011 Oct; 100(10):4050-73. PubMed ID: 21523782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PK/DB: database for pharmacokinetic properties and predictive in silico ADME models.
    Moda TL; Torres LG; Carrara AE; Andricopulo AD
    Bioinformatics; 2008 Oct; 24(19):2270-1. PubMed ID: 18684738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-throughput and in silico techniques in drug metabolism and pharmacokinetics.
    van de Waterbeemd H
    Curr Opin Drug Discov Devel; 2002 Jan; 5(1):33-43. PubMed ID: 11865671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting ADME properties in silico: methods and models.
    Butina D; Segall MD; Frankcombe K
    Drug Discov Today; 2002 Jun; 7(11):S83-8. PubMed ID: 12047885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-dimensional (2D) in silico models for absorption, distribution, metabolism, excretion and toxicity (ADME/T) in drug discovery.
    Khakar PS
    Curr Top Med Chem; 2010; 10(1):116-26. PubMed ID: 19929825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High throughput ADME screening: practical considerations, impact on the portfolio and enabler of in silico ADME models.
    Hop CE; Cole MJ; Davidson RE; Duignan DB; Federico J; Janiszewski JS; Jenkins K; Krueger S; Lebowitz R; Liston TE; Mitchell W; Snyder M; Steyn SJ; Soglia JR; Taylor C; Troutman MD; Umland J; West M; Whalen KM; Zelesky V; Zhao SX
    Curr Drug Metab; 2008 Nov; 9(9):847-53. PubMed ID: 18991580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systems-ADME/Tox: resources and network approaches.
    Ekins S
    J Pharmacol Toxicol Methods; 2006; 53(1):38-66. PubMed ID: 16054403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In silico ADME/T modelling for rational drug design.
    Wang Y; Xing J; Xu Y; Zhou N; Peng J; Xiong Z; Liu X; Luo X; Luo C; Chen K; Zheng M; Jiang H
    Q Rev Biophys; 2015 Nov; 48(4):488-515. PubMed ID: 26328949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can the Internet help to meet the challenges in ADME and e-ADME?
    Van de Waterbeemd H; De Groot M
    SAR QSAR Environ Res; 2002; 13(3-4):391-401. PubMed ID: 12184380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Silico Absorption, Distribution, Metabolism, Excretion, and Pharmacokinetics (ADME-PK): Utility and Best Practices. An Industry Perspective from the International Consortium for Innovation through Quality in Pharmaceutical Development.
    Lombardo F; Desai PV; Arimoto R; Desino KE; Fischer H; Keefer CE; Petersson C; Winiwarter S; Broccatelli F
    J Med Chem; 2017 Nov; 60(22):9097-9113. PubMed ID: 28609624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Applying machine learning techniques for ADME-Tox prediction: a review.
    Maltarollo VG; Gertrudes JC; Oliveira PR; Honorio KM
    Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):259-71. PubMed ID: 25440524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In silico prediction of ADME and pharmacokinetics. Report of an expert meeting organised by COST B15.
    Boobis A; Gundert-Remy U; Kremers P; Macheras P; Pelkonen O
    Eur J Pharm Sci; 2002 Dec; 17(4-5):183-93. PubMed ID: 12453607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Precompetitive preclinical ADME/Tox data: set it free on the web to facilitate computational model building and assist drug development.
    Ekins S; Williams AJ
    Lab Chip; 2010 Jan; 10(1):13-22. PubMed ID: 20024044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.